ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.

Data from the following clinical trials are discussed:

  • 3721: Characterization of Bruton tyrosine kinase inhibitor (BTKi)-related adverse events in a head-to-head trial acalabrutinib versus ibrutinib in previously chronic lymphocytic leukemia (CLL)
  • 68: First-line treatment with ibrutinib (Ibr) plus venetoclax (Ven) for chronic lymphocytic leukemia (CLL): 2-year post-randomization disease-free survival (DFS) results from the minimal residual disease (MRD) cohort of the phase 2 Captivate study
  • 396: SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
  • 67: Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from arm D of the SEQUOIA (BGB-311-304) trial
  • 1410: Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (Pts) with relapsed/refractory B-cell malignancies
  • 395: A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): a minimal residual disease (MRD)-driven, time-limited approach
  • 391: Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study

Supported in part by Takeda Oncology. Content developed independently by Onclive®.

Related Videos
View All
Related Content